UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
Recruiting
Phase 1
Phase 2
Interventional Study
Peanut-Induced Anaphylaxis
Peanut Allergy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 55
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 40 (estimated)
- Sponsor
- Ukko Inc · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults 18-55 years old
* documented history of physician-diagnosed peanut allergy
* positive skin prick test (SPT)
* screening DBPCFC peanut protein
* contraception use should be consistent with local regulations
* capable of providing signed written informed consent
Exclusio…
Contacts